Professor of Medicine, University Iowa College of Medicine
Oncology
Dr. Gerald H. Clamon, MD
|
|
Give Review
Gerald Clamon is an expert in the field of Oncology. He went to Washington University School of Medicine in St. Louis. Gerald Clamon is a published doctor. He has 68 papers published. The most current publication "A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewin..." Gerald Clamon accepts Medicare payments and is listed with Medicare.gov.
Publications
- Germline mutations predisposing to non-small cell lung Cancer.
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- Adverse events associated with concurrent chemoradiation therapy in patients with head and neck Cancer.
- Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung Cancer.
- Is planned neck dissection necessary for head and neck Cancer after intensity-modulated radiotherapy?
- Changing failure patterns in oropharyngeal squamous cell Carcinoma treated with intensity modulated radiotherapy and implications for future research.
- Non-Hodgkin's Lymphoma of the head and neck: the University of Iowa experience.
- Small cell lung Carcinoma in the elderly.
- High-dose cyclophosphamide and adriamycin with DTIC maintenance for metastatic soft tissue sarcomas.
- Screening for depression and anxiety in Cancer patients using the Hospital Anxiety and Depression Scale.
- Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid.
- Etoposide for small cell lung Cancer.
- Epitheliotropic lymphoma of the small bowel. Report of a fatal case with cytotoxic/suppressor T-Cell immunotype.
- Leptomeningeal Carcinomatosis following craniofacial resection of an ethmoid tumor.
- Distress associated with Cancer as measured by the illness distress scale.
- Establishment and characterization of four new human non-small cell lung Cancer cell lines.
- Relationship between tumor area, tumor volume, and criteria of response in clinical trials.
- Constitutional symptoms in patients with germ cell Neoplasms.
- Rapid relief of anxiety in Cancer patients with both alprazolam and placebo.
- Silver-stained nucleolar organizer regions in the differentiation of prostatic hyperplasia, intraepithelial neoplasia, and adenoCarcinoma.
- Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
- Meningeal carcinomatosis from breast Cancer: spinal cord vs. brain involvement.
- Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents.
- Phase 2 trial of streptozotocin by continuous infusion for metastatic coloRectal carcinoma.
- Serum folate and vitamin B12 levels in patients with small cell lung Cancer.
- Patterns of bone marrow involvement with small cell lung Cancer.
- Salvage therapy of aggressive non-Hodgkin's Lymphoma with a combination of vinblastine, bleomycin, and cisplatin.
- Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung Cancer.
- The effect of intravenous hyperalimentation on the dietary intake of patients with small cell lung Cancer. A randomized trial.
- Response of inTractable pain to continuous intrathecal morphine: a retrospective study.
- Myasthenic syndrome and small cell Cancer of the lung. Variable response to antineoplastic therapy.
- Short course prophylactic cranial irradiation for small cell lung Cancer.
- Kinetically scheduled therapy for extensive small-cell lung Cancer.
- Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung Cancer: a randomized trial.
- Radiotherapy plus razoxane for advanced limited extent Carcinoma of the lung.
- Phase II study of dibromodulcitol and BCNU in metastatic Malignant melanoma.
- Effects of intravenous hyperalimentation during treatment in patients with small-cell lung Cancer.
- A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewin...
- Carboplatin in non-small cell lung Cancer: an update on the Cancer and Leukemia Group B experience.
- Phase II trial of edatrexate in patients with metastatic colorectal Cancer.
- High-dose paclitaxel plus G-CSF for Malignant mesothelioma: CALGB phase II study 9234.
- Trimetrexate in untreated and previously treated patients with metastatic breast Cancer: a Cancer and Leukemia Group B study.
- Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung Cancer.
- A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-sm...
- Nonoperative management of non-small cell lung Cancer: the current Cancer and leukemia group B experience.
- A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung Cancer: a Cancer and Leukemia Gr...
- Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung Cancer: analysis of factors influencing survival and toxicity.
- Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.
- A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung Cancer: a Cancer and leukemia group B study.
- A phase I/II trial of etoposide and cisplatin in extensive small cell lung Cancer: a Cancer and leukemia group B study.
- Recruiting Cancer patients to participate in motivating their relatives to quit smoking. A Cancer control study of the Cancer and Leukemia Group B (CALGB 9072).
- Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung Cancer.
- Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck Cancer.
- Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung Cancer: a Cancer and Leukemia Group B study (CALGB 8832).
- A feasibility study of extended chemotherapy for locally advanced non-small cell lung Cancer: a phase II trial of Cancer and leukemia group B.
- Interleukin-2 activity in patients with extensive small-cell lung Cancer: a phase II trial of Cancer and Leukemia Group B.
- Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung Cancer (NSCLC): a meta-analysis of individual data from ...
- Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung Cancer: a phase II trial of Cancer and Leukemia Group B.
- Phase I clinical study of fish oil fatty acid capsules for patients with Cancer cachexia: Cancer and leukemia group B study 9473.
- Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung Cancer: a phase III trial of the Cancer and Leukemia Group B and the E...
- Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.
- Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.
- Concurrent chemoradiotherapy for unresectable stage III non-small cell lung Cancer.
- Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
- Phase II study of high-dose fish oil capsules for patients with Cancer-related cachexia.
- A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate Cancer: results of Cancer and leukemia group B trial 90004.
- Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung Cancer.
Schools
Washington Center School of Medicine
Barnes Jewish Hospital
National Cancer Institute
University Ia
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Iowa Hospitals and Clinics -
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Drug Facts
| NPI NUMBER | 1114902913 | |
| NPPES Provider LastName | CLAMON | |
| NPPES Provider FirstName | GERALD | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 952.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 105.0 | |
| Percent Opioid Claims | 11.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114902913 |
| Last Name Of The Provider | CLAMON |
| First Name Of The Provider | GERALD |
| View All |
Similar Doctors
|
|
Dr. James E. Feeley, MD |
|
|
Dr. Yousef Zakharia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark W. El-Deiry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laith I. Abushahin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammed M. Milhem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Berg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamal K. Abbi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ali Naderi, MD
This Doctor is OpenDoctor Recommended.
|